Quantcast

Latest Biologic Stories

2014-03-21 23:00:27

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Adalimumab Market, 2010-2018” to its store. Dallas, TX (PRWEB) March 22, 2014 Adalimumab is a TNF (tumor necrosis factor) inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and...

2014-03-19 08:29:30

BEIJING, March 19, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has received the Good Manufacturing Practice ("GMP") certification from China Food and Drug Administration ("CFDA") in respect of its plasma production facility at its Guizhou subsidiary. Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of...

2014-03-14 04:20:45

REYKJAVIK, Iceland, March 14, 2014 /PRNewswire/ -- Alvotech, a powerful new player in the field of biopharmaceuticals and Finesse Solutions, Inc. ("Finesse"), today announce that they have entered into a partnership that will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory® GMP manufacturing platform suite. SmartFactory® is a single-use cGMP bio-manufacturing capacity, which...

2014-03-13 16:27:50

DUBLIN, Ireland, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/34kmnx/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" [http://www.researchandmarkets.com/research/34kmnx/global_biosimilar ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global biosimilars market is at a crucial turning point, as...

2014-03-12 23:32:05

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it will launch its new ADVASEPT (TM) technology, for the advanced aseptic filling of injectable drugs, at the forthcoming INTERPHEX exhibition, which takes place from the 18th to the 20th of March at the Javits Center, New York City, NY. Somerset, NJ (PRWEB) March 11, 2014 Catalent Pharma Solutions, the...

2014-03-11 23:22:29

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it will launch its new ADVASEPTTM technology, for the advanced aseptic filling of injectable drugs, at the forthcoming INTERPHEX exhibition, which takes place from the 18th to the 20th of March at the Javits Center, New York City, NY. Somerset, NJ (PRWEB) March 11, 2014 Catalent Pharma Solutions, the...

2014-03-11 16:25:50

AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing portfolio around its lead product candidate. The new patent grants XBiotech exclusive rights to target a unique molecule associated with chronic sterile inflammation. The patent relates to antibodies and methods of using these antibodies to treat, prevent, and detect disease progression associated...

2014-03-11 08:28:39

SAN ANTONIO, March 11, 2014 /PRNewswire/ -- Aperion Biologics, Inc., a clinical-stage regenerative medical device company, announced that France Dixon Helfer and Mike Ward were appointed to the Company's Board of Directors. Ms. Helfer currently serves as President and Chief Executive Officer of Halo Healthcare Inc., a medical device and diagnostics company which develops innovative technologies for early risk detection of breast cancer. Most recently, she was the founder and CEO of...

2014-03-10 08:28:58

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). The patent includes claims to...

2014-03-06 23:04:31

Catalent Pharma Solutions, the global leader in advanced delivery technologies and development solutions for drug, biologic and consumer health products, today announced an agreement with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans. Somerset, NJ (PRWEB) March 06, 2014 Catalent Pharma Solutions, the global...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.